Immunotech Biopharm Ltd
Research Immunotech Biopharm Ltd (6978.HK) on Bullrun: market cap HKD 237.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6978.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 237.74M
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 230.79M
- Free cash flow-CNY 111.92M
Valuation Snapshot
latest market cap is HKD 237.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 230.79M | -CNY 111.92M | n/a | -0.42 | CNY 54.46M | CNY 440.26M | -CNY 13.93M |
| FY2024 | CNY 0 | -CNY 186.91M | -CNY 153.81M | n/a | -0.33 | CNY 46.96M | CNY 384.56M | -CNY 13.30M |
| FY2023 | CNY 0 | -CNY 334.82M | -CNY 186.17M | n/a | -0.6 | CNY 52.16M | CNY 457.17M | CNY 173.62M |
| FY2022 | CNY 0 | -CNY 318.11M | -CNY 277.49M | n/a | -0.57 | CNY 58.45M | CNY 149.81M | CNY 508.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 237.74M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immunotech Biopharm Ltd's market cap?
Immunotech Biopharm Ltd's market capitalization is HKD 237.74M.
What does Immunotech Biopharm Ltd do?
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. The company's core product is EAL, a multi-target cellular immunotherapy product that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer.